A Two-Part Study in Japanese Patients With Advanced or Metastatic NSCLC. Open-Label Phase I to Assess the Safety & Tolerability of AZD2171 in Combination With Pac/Carb, Then a Phase II, Randomised, Double-Blind Study to Assess the Efficacy of Pac/Carb Alone and in Combination With AZD2171 and Pac/Carb
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
PART A : Safety and tolerability of AZD2171 in combination with pac/carbo in patients with non-small cell lung cancer
Assessed at each visit during Part A
No
Jane Robertson
Study Director
AstraZeneca
Japan: Pharmaceuticals and Medical Devices Agency
D8480C00040
NCT00539331
September 2007
September 2008
Name | Location |
---|